Development of an Integrated Assay for Detection of BCR-ABL RNA | Zendy

Emily S. Winn-Deen | Zendy; Bret Helton | Zendy; Reuel Van Atta | Zendy; Wendy Wong | Zendy; Jeffrey Peralta | Zendy; James Wang | Zendy; Gregory J. Tsongalis | Zendy; Dorothy R. Belloni | Zendy; David W. Chan | Zendy; James R. Eshleman | Zendy; Christopher D. Gocke | Zendy; Zsolt Jobbágy | Zendy; Lan Beppu | Zendy; Jerald P. Radich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of an Integrated Assay for Detection of BCR-ABL RNA

Author(s) -

Emily S. Winn-Deen,

Bret Helton,

Reuel Van Atta,

Wendy Wong,

Jeffrey Peralta,

James Wang,

Gregory J. Tsongalis,

Dorothy R. Belloni,

David W. Chan,

James R. Eshleman,

Christopher D. Gocke,

Zsolt Jobbágy,

Lan Beppu,

Jerald P. Radich

Publication year - 2007

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2007.085472

Subject(s) - chronic myelogenous leukemia , abl , real time polymerase chain reaction , breakpoint cluster region , medicine , biology , leukemia , immunology , tyrosine kinase , genetics , receptor , gene

Current practice guidelines for managing patients with chronic myelogenous leukemia (CML) call for monitoring BCR-ABL transcript concentrations with a quantitative reverse transcription-PCR (qRT-PCR) assay. Because the available laboratory-developed assays lack consensus on the appropriate design, reporting of results, and reference intervals, we developed and evaluated an integrated BCR-ABL assay that yields standardized results for any laboratory and can be performed by technicians with no specialized training.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research